Rigel Pharmaceuticals (RIGL)
Rigel Pharmaceuticals Revenue Growth
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
RIGL Revenue Growth Range, Past 5 Years
| Minimum | -99.20% | Jun 2011 |
| Maximum | 155.8% | Dec 2007 |
| Average | -30.94% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these RIGL related companies
RIGL News
Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease
May 16, 7:30AM PR Newswire
May 16, 7:30AM PR Newswire
$RIGL 200 Day SMA Cross - Price crossed above 200 day SMA (8.0687). Confirmed by volume.
about 21 days ago by TradeIdeasQuant
about 21 days ago by TradeIdeasQuant
@WolfpackInvest i have a ton of longs but just traded $RIGL and $P for gains now just chiling wait for A+ set ups
about 23 days ago by brysenp
about 23 days ago by brysenp
$RIGL http://stks.co/3VeC Strong pipleine for tx of asthma and arthritis. Offering entry here at support. Long
about 36 days ago by Catalystrader
about 36 days ago by Catalystrader
$RIGL filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3KQP
about 49 days ago by MarketBrief
about 49 days ago by MarketBrief
Correction: We exited $UTX and $MNRO today for profit. Still Long $PODD and $RIGL
about 66 days ago by ScholzCapital
about 66 days ago by ScholzCapital
We exited $PODD and $RIGL both for profit. will post charts later
about 66 days ago by ScholzCapital
about 66 days ago by ScholzCapital
Piper Jaffary Reiterates Overweight on Rigel Pharmaceuticals ahead of Phase III Data
Mar 06, 9:04AM Benzinga
Mar 06, 9:04AM Benzinga
Rigel Pharmaceuticals (RIGL) Posts Wider than Expected Q4 Loss of 36c/Share
Mar 06, 7:36AM Street Insider
Mar 06, 7:36AM Street Insider
$RIGL http://stks.co/1o8W on watch list - very light vol today - but biotech been pretty good and this near line so watch
about 146 days ago by StockTiger
about 146 days ago by StockTiger
Rigel Pharmaceuticals (RIGL) Initiates Clinical Trials on R548 and R333 During Q4
Jan 05, 7:37AM Street Insider
Jan 05, 7:37AM Street Insider
RT @StockTiger Market Wrap Video + Additions to Watch List http://stks.co/1l4P including $AONE $MOTR $SIGA $SFY $ATLS $RIGL
about 149 days ago by 1973Hog
about 149 days ago by 1973Hog
Market Wrap Video + Additions to Watch List http://stks.co/1l46 including $AONE $MOTR $SIGA $SFY $ATLS $RIGL
about 149 days ago by StockTiger
about 149 days ago by StockTiger
$RIGL Upside Blowoff - 15 Minute Down Reversal - Red bar after 5 higher highs and higher lows
about 149 days ago by TradeIdeasQuant
about 149 days ago by TradeIdeasQuant
Comments in the Financial Times yesterday indicates that Piper Jaffrey has indicated that $RIGL would make an ideal buyout target for $AZN
about 224 days ago by sld1986
about 224 days ago by sld1986
Jefferies Maintains a 'Buy' on Rigel Pharmaceuticals (RIGL); Update On R343 And Early Pipeline
Oct 14, 8:21AM Street Insider
Oct 14, 8:21AM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| RIGL | 7.42 | -0.07 | -0.93% | 535.09M |
| RIG | 40.83 | -0.53 | -1.28% | 14.49B |
| RICK | 7.88 | -0.01 | -0.13% | 76.30M |
| RIC | 5.86 | -0.16 | -2.66% | 199.92M |
| RHT | 51.35 | -0.18 | -0.35% | 9.953B |
| RES | 10.39 | -0.25 | -2.35% | 2.335B |
| RENT | 16.28 | +0.07 | +0.43% | 178.31M |
| RENN | 4.74 | +0.19 | +4.18% | 1.168B |
| REN | 8.75 | +0.11 | +1.27% | 526.52M |
| REMX | 13.49 | -0.06 | -0.47% |
